Heart Of Diabetes EMPA-REG Outcome Study Meeting
Boehringer Ingelheim and Eli Lilly are excited to invite you to a meeting, which is part of our national education program, discussing the latest breakthrough with JARDIANCE® (empagliflozin) in reducing the risk of cardiovascular death for patients with type 2 diabetes and established cardiovascular disease (CAD, PAD, MI or stroke) on top of standard of…
